Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds. Issue 4 (16th March 2023)

• Record Type: Journal Article
• Authors: Simões, Eric A F; Klein, Nicola P; Sabharwal, Charu; Gurtman, Alejandra; Kitchin, Nicholas; Ukkonen, Benita; Korbal, Piotr; Zou, Jing; Xie, Xuping; Sarwar, Uzma N; Xu, Xia; Lockhart, Stephen; Cunliffe, Luke; Lu, Claire; Ma, Hua; Swanson, Kena A; Koury, Kenneth; Shi, Pei-Yong; Cooper, David; Türeci, Ӧzlem; Jansen, Kathrin U; Şahin, Uğur; Gruber, William C
• Is Part Of: Journal of the Pediatric Infectious Diseases Society. Volume 12:Issue 4(2023)
• Page Start: 234
• Page End: 238
• Publication Date: 2023-03-16
• Subjects: COVID-19 -- BNT162b2 vaccine -- children -- booster -- immunogenicity -- safety; Communicable diseases in children -- Periodicals; Children -- Diseases -- Periodicals; 618.929
• DOI: 10.1093/jpids/piad015
• Languages: English
• ISSNs: 2048-7193

Abstract

Abstract: In this ongoing study, substantially increased ancestral SARS-CoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After dose 3, increased neutralizing responses against Omicron BA.1 and BA.4/BA.5 strains were also observed. The safety/tolerability profile was acceptable. (NCT04816643) Abstract : A third BNT162b2 10-µg vaccine dose administered approximately 6 months after the second dose to 5- to 11-year olds increased neutralizing titers, including against Omicron BA.1 and BA.4/BA.5 strains. The safety and tolerability profile of the third BNT162b2 10-µg dose was acceptable.